Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

mesangial proliferative glomerulonephritis - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

mesangial proliferative glomerulonephritis

MONDO:0003139

Also known as:Mesangioproliferative glomerulonephritisglomerulonephritis - mesangial proliferativemesangial proliferative GN

Overview

Mesangial proliferative glomerulonephritis (MPGN) is a condition that affects the kidneys. Many experts consider it a variant of minimal change disease, but some experts believe it is a separate condition. It may present with nephrotic syndrome, which is a group of symptoms that include protein in the urine (proteinuria), low blood protein levels, high cholesterol levels, high triglyceride levels, and swelling. It can also present with blood in the urine (hematuria). MPGN is characterized by an increased number of mesangial cells in the glomeruli in the kidneys and damage to the glomeruli. Glomeruli are the structures that help filter wastes and fluids. MPGN may occur in several renal diseases such as IgA nephropathy (commonly), IgM nephropathy, lupus nephritis, and C1q nephropathy.However, in some cases, the underlying cause of MPGN remains unclear. Treatment may depend on the cause (if known) and may include steroids, mycophenolate mofetil, and/or cyclophosphamide, and other therapies to treat specific symptoms. Most people with MPGN have a good prognosis, but some may develop chronic kidney disease, which can progress to end stage renal failure.

Diagnosis

Biomarker and diagnostic research for mesangial proliferative glomerulonephritis has been reported in the published literature.

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for mesangial proliferative glomerulonephritis.

48 publications have been identified in PubMed for mesangial proliferative glomerulonephritis. Research spans Case Report / Case Series (42%), Basic Science / Preclinical (15%), and Epidemiology / Natural History (10%).

Research Type	Count	% of Total
Patient case studies	20	42%

Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 6:54 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

GARD

Genetic and Rare Diseases Info Center

GARD:9580

Questions for Your Care Team

→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Kisho

mesangial proliferative glomerulonephritis

Overview

Diagnosis

Research Landscape

Medical References

External Resources

GARD

Questions for Your Care Team

Questions for Your Care Team

Recent Publications

Latest News & Developments

Late Presentation of de Novo Proliferative Glomerulonephritis With Monoclonal IgG Deposits in a Renal Allograft: A Rare Case With an Unusual Clinical Course.

Inconsistency between serum IgG κ and glomerular IgA λ chain types in proliferative glomerulonephritis with monoclonal deposits successfully treated with daratumumab-based therapy.

mesangial proliferative glomerulonephritis

Overview

Diagnosis

Research Landscape

Medical References

External Resources

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Recent Publications

Latest News & Developments

Late Presentation of de Novo Proliferative Glomerulonephritis With Monoclonal IgG Deposits in a Renal Allograft: A Rare Case With an Unusual Clinical Course.

Inconsistency between serum IgG κ and glomerular IgA λ chain types in proliferative glomerulonephritis with monoclonal deposits successfully treated with daratumumab-based therapy.